Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (888) 282-7099 Click to print page  Print

Browse Trials


In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.


Currently viewing trials
(Last updated: December 03, 2021)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2 (inherited)

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

Close

AKT

ALK

AR

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

RB

ROS1

TP53

1

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 3-6 visits every month

PHASE: I

NCT ID: NCT04756505

Immunotherapy and Radiation Therapy for HR+, HER2- Metastatic Breast Cancer

REINA: A Phase I Study of Radiation Enhanced IL 12-Necrosis Attraction in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients Scientific Title

Purpose
To determine the best dose, effects (good and bad), and anti-cancer activity of giving the immunotherapies NHS-IL12 and bintrafusp alfa along with radiation therapy.
Who is this for?
People with metastatic (stage IV) hormone-positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have at least 2 sites of metastatic disease and have received at least one hormone therapy for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bintrafusp alfa, by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">NHS-IL12, by injection, once a month </li> <li class="seamTextUnorderedListItem">Radiation therapy, daily for 1-4 days, every month</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NHS-IL12 is an investigational immunotherapy.</li> <li class="seamTextUnorderedListItem">Bintrafusp alfa (M7824) is an investigational immunotherapy. It is designed to get the immune system to go after cancer cells by blocking the proteins PD-L1 and TGF-beta. </li> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04756505' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dovepress.com/nhs-il12-a-tumor-targeting-immunocytokine-peer-reviewed-fulltext-article-ITT' target='_blank'>Dove Press Journal Abstract: NHS-IL12</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/radiation' target='_blank'>Breastcancer.org: Radiation therapy</a> </li></ul>
See more